AKTS Stock Forecast: Aktis Oncology, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Aktis Oncology, Inc. hold a median 12-month price target of $34 — +50.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
AKTS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Aktis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (56): Analysts have, on balance, been raising their forecasts.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Aktis Oncology, Inc. — and when they’d sell — is the membership.
AKTS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AKTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +50.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 July 2026 | JP Morgan | Maintains | Overweight | $30 → $33 |
| 16 June 2026 | Raymond James | Initiates | Strong Buy | $40 |
| 16 June 2026 | Raymond James | Initiates | Strong Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Apr 2026 | William Blair | Initiates | Outperform | — |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 3 Feb 2026 | JP Morgan | Initiates | Overweight | — |
| 3 Feb 2026 | Leerink Partners | Initiates | Outperform | — |
| 4 Jan 2024 | Piper Sandler | Downgrade | Neutral | — |
| 7 Sept 2023 | B. Riley Securities | Downgrade | Neutral | — |
| 7 Sept 2023 | Oppenheimer | Maintains | Outperform | — |
| 9 May 2023 | Oppenheimer | Maintains | Outperform | — |
| 9 May 2023 | Roth MKM | Maintains | Buy | — |
| 24 Jan 2023 | B. Riley Securities | Initiates | Buy | — |
| 15 Nov 2022 | Oppenheimer | Maintains | Outperform | — |
| 13 Sept 2022 | Piper Sandler | Maintains | Overweight | — |
| 3 May 2022 | Piper Sandler | Maintains | Overweight | — |
| 2 Nov 2021 | Oppenheimer | Maintains | Outperform | — |
| 4 May 2021 | Roth Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AKTS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Aktis Oncology, Inc. (AKTS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −18.2×
- Price / sales
- 147.4×
- Price / book
- 2.4×
- EV / EBITDA
- −9.0×
Cheaper than 96% of US stocks
Cheaper than 3% of US stocks
Cheaper than 40% of US stocks
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- 123.0%
- Earnings growth (YoY)
- −64.3%
- Gross margin
- —
- Operating margin
- −703.6%
- Net margin
- 0.0%
Higher than 95% of US stocks
Higher than 7% of US stocks
Higher than 7% of US stocks
Higher than 30% of US stocks
- Return on equity
- 43.6%
- Return on assets
- −24.1%
- Dividend yield
- —
Higher than 92% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AKTS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AKTS appears on the weeks it earns a place.
Frequently asked questions about AKTS stock
What is the AKTS stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Aktis Oncology, Inc. have a median 12-month price target of $34, with estimates ranging from $31 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AKTS stock a buy right now?
Of the 7 analysts covering Aktis Oncology, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aktis Oncology, Inc. 2 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AKTS?
As at 1 Aug 2026, Aktis Oncology, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (56 of 100).
Will AKTS stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +50.7% from the last close, and Ticker Nerd's factor model ranks Aktis Oncology, Inc. 2 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AKTS stock forecast for 2030?
No analyst covering Aktis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AKTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $40 over the next 12 months.
What does Aktis Oncology, Inc. do?
Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets.
About Aktis Oncology, Inc.
Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets. It leverages proprietary bulk acoustic wave (BAW) technology, including its microelectromechanical system (MEMS)-based XBAW manufacturing process, to produce high-performance filters optimized for high power, high frequency, and wide bandwidth applications. The company operates through two primary segments: Fabrication Services, which offers engineering review and backend packaging services, and RF Filters, focused on amplifier and filter product sales. Its solutions serve critical applications in smartphones, tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense systems. Akoustis Technologies Inc. also provides complementary products such as surface acoustic wave resonators, crystal resonators and oscillators, ceramic products, and back-end semiconductor supply chain services. Headquartered in Huntersville, North Carolina, the company plays a specialized role in advancing RF front-end modules for next-generation wireless connectivity.
CEO Dr. Matthew Roden Ph.D. · 79 employees · United States · https://www.aktisoncology.com